On February 18, 2021, zr pharma& GmbH (“pharma&”) signed an agreement with F. Hoffmann-La Roche Ltd to acquire the worldwide rights of Pegasys® (peginterferon alfa 2a) excluding China and Japan. The pharma& US distributor for Pegasys will be Summit SD located in Missouri.
Please direct any clinical product questions to pharma& by phone at (888) 814-7PEG (7734).
Who should I contact if I have side effect concerns or have an adverse event to report on the product?
Beginning January 4, 2022, you may contact pharma& for both pharma& and Genentech Pegasys products by email: [email protected] or phone: (888) 814-7PEG (7734) if you have side effect concerns or you would like to report an adverse event. You may also report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.